Patient-Reported and Toxicity Results from the FABREC Study: A Multicenter Randomized Trial of Hypofractionated vs. Conventionally-Fractionated Postmastectomy Radiation Therapy after Implant-Based Reconstruction
Julia S. Wong(Brigham and Women's Hospital), Rinaa S. Punglia(Dana-Farber Cancer Institute), Jean L. Wright(University of North Carolina at Chapel Hill), J.N. Kim(University of Washington), C.C. Park(University of California, San Francisco), Chiara Pellegrini(Dana-Farber Cancer Institute), Alice Y. Ho(Houston Methodist), Matthew D. Cheney(Maine Medical Center), R. Shiloh(Brigham and Women's Hospital), Angela C. Tramontano(Massachusetts General Hospital), Meena S. Moran(Cleveland Clinic), Laura Warren(Dana-Farber Cancer Institute), Kathleen C. Horst(Stanford University), Alphonse G. Taghian(Massachusetts General Hospital), Hajime Uno(Dana-Farber Cancer Institute), K.L. Leonard(Brown University), Y Chun(Brigham and Women's Hospital), Jennifer R. Bellon(Brigham and Women's Hospital), A. Recht(Beth Israel Deaconess Medical Center), Patricia H. Hardenbergh
International Journal of Radiation Oncology*Biology*Physics
October 12, 2023
Cited by 23
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
|Statistics in Medicine|2011|1.5k
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
|Journal of Clinical Oncology|2014|777
Ductal Carcinoma in Situ of the Breast
|New England Journal of Medicine|2004|758
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
|Practical Radiation Oncology|2018|615